Hansoh Pharmaceutical (03692): Phase III clinical study of HS-10374 for moderate-to-severe plaque psoriasis meets co-primary endpoints

Zhito Finance APP News, Hansoh Pharmaceutical (03692) announced that the Group's self-developed tyrosine kinase 2 (TYK2) selective allosteric inhibitor HS-10374 has met the co-primary endpoints in a pivotal Phase III clinical trial for moderate-to-severe plaque psoriasis in adults: at Week 16 of treatment, the proportion of patients in the HS-10374 group achieving at least a 75% reduction from baseline in the Psoriasis Area and Severity Index (PASI 75), and the proportion achieving a static Physician's Global Assessment (sPGA) score of 0 or 1 with at least a 2-point reduction from baseline (sPGA 0/1), were both significantly higher than those in the placebo group. The trial also met multiple secondary endpoints: at Week 16, more than half of the patients treated with HS-10374 achieved PASI 90 response, and nearly one-third achieved PASI 100 response. Meanwhile, HS-10374 demonstrated a favorable safety and tolerability profile, with its safety characteristics similar to those of other TYK2 inhibitors in the same class, and no new safety signals were observed.